$OPRX
OptimizeRx Corp Stock $oprx

$oprx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000121390023039060 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$13.82M	$13.00M	$13.73M
YoY Change	-1.15%	-5.31%	22.28%
Cost Of Revenue	$5.993M	$5.570M	$5.630M
YoY Change	20.13%	-1.07%	10.39%
Gross Profit	$7.825M	$7.433M	$8.102M
YoY Change	-12.96%	-8.25%	32.38%
Gross Profit Margin	56.63%	57.17%	59.0%
Selling, General & Admin	$12.24M	$14.03M	$11.39M
YoY Change	-0.63%	23.19%	90.49%
% of Gross Profit	156.45%	188.78%	140.6%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$464.8K	$463.9K	$471.5K
YoY Change	-19.61%	-1.61%	-11.03%
% of Gross Profit	5.94%	6.24%	5.82%
Operating Expenses	$12.71M	$14.50M	$11.86M
YoY Change	-1.49%	22.2%	75.23%
Operating Profit	-$4.882M	-$7.063M	-$3.761M
YoY Change	24.9%	87.8%	478.63%
Interest Expense	$720.4K	$665.5K	$0.00
YoY Change	2924.43%
% of Operating Profit
Other Income/Expense, Net	$720.4K	$665.5K	$3.00
YoY Change	2924.94%	22182300.0%
Pretax Income	-$4.161M	-$6.398M	-$3.761M
YoY Change	7.12%	70.1%	487.67%
Income Tax
% Of Pretax Income
Net Earnings	-$4.161M	-$6.398M	-$3.761M
YoY Change	7.12%	70.1%	487.67%
Net Earnings / Revenue	-30.12%	-49.2%	-27.39%
Basic Earnings Per Share	-$0.24	-$0.37	-$0.21
Diluted Earnings Per Share	-$0.24	-$0.37	-$210.4K
COMMON SHARES
Basic Shares Outstanding	17.13M shares	17.10M shares	17.88M shares
Diluted Shares Outstanding	16.99M shares	17.09M shares	17.88M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$62.74M	$73.70M	$88.95M
YoY Change	-28.21%	-17.15%	8.09%
Cash & Equivalents	$9.808M	$16.44M	$88.95M
Short-Term Investments	$52.93M	$57.26M
Other Short-Term Assets	$4.053M	$4.015M	$4.609M
YoY Change	-5.33%	-12.9%	31.7%
Inventory
Prepaid Expenses
Receivables	$18.28M	$18.16M	$19.14M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$85.07M	$95.88M	$112.7M
YoY Change	-22.94%	-14.92%	12.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$141.0K	$143.9K	$137.4K
YoY Change	-66.58%	4.72%	-77.09%
Goodwill	$22.67M	$22.67M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets			$12.86K
YoY Change
Total Long-Term Assets	$36.25M	$35.81M	$25.44M
YoY Change	-2.13%	40.77%	-6.13%
TOTAL ASSETS
Total Short-Term Assets	$85.07M	$95.88M	$112.7M
Total Long-Term Assets	$36.25M	$35.81M	$25.44M
Total Assets	$121.3M	$131.7M	$138.1M
YoY Change	-17.72%	-4.67%	8.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$817.8K	$1.289M	$600.7K
YoY Change	-36.9%	114.55%	20.15%
Accrued Expenses	$1.503M	$2.125M	$1.806M
YoY Change	-12.92%	17.67%	80.56%
Deferred Revenue	$451.0K	$735.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.510M	$7.606M	$6.875M
YoY Change	-14.46%	10.62%	27.32%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$123.2K	$213.0K
YoY Change	-100.0%	-42.13%	-29.02%
Total Long-Term Liabilities	$0.00	$123.2K	$213.0K
YoY Change	-100.0%	-42.13%	-29.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.510M	$7.606M	$6.875M
Total Long-Term Liabilities	$0.00	$123.2K	$213.0K
Total Liabilities	$5.510M	$7.729M	$7.088M
YoY Change	-16.91%	9.04%	24.35%
SHAREHOLDERS EQUITY
Retained Earnings	-$57.25M	-$53.09M
YoY Change
Common Stock	$18.38K	$18.33K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.741K	$1.214K
YoY Change
Treasury Stock Shares
Shareholders Equity	$115.8M	$124.0M	$131.1M
YoY Change
Total Liabilities & Shareholders Equity	$121.3M	$131.7M	$138.1M
YoY Change	-17.72%	-4.67%	8.26%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.161M	-$6.398M	-$3.761M
YoY Change	7.12%	70.1%	487.67%
Depreciation, Depletion And Amortization	$464.8K	$463.9K	$471.5K
YoY Change	-19.61%	-1.61%	-11.03%
Cash From Operating Activities	-$2.368M	-$86.33K	$4.080M
YoY Change	-868.56%	-102.12%	144.33%
INVESTING ACTIVITIES
Capital Expenditures	$1.103M	$28.58K	-$14.48K
YoY Change	-4207.56%	-297.38%	-81.9%
Acquisitions
YoY Change
Other Investing Activities	$4.326M	-$1.326M	-$51.27K
YoY Change	-306.61%	2487.11%
Cash From Investing Activities	$3.223M	-$1.549M	-$65.75K
YoY Change	-251.97%	2255.73%	-17.81%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-7.490M	-$129.8K	258.1K
YoY Change	-3080.74%	-150.28%	-99.63%
NET CHANGE
Cash From Operating Activities	-2.368M	-$86.33K	4.080M
Cash From Investing Activities	3.223M	-$1.549M	-65.75K
Cash From Financing Activities	-7.490M	-$129.8K	258.1K
Net Change In Cash	-6.635M	-$1.765M	4.273M
YoY Change	324.96%	-141.31%	-94.05%
FREE CASH FLOW
Cash From Operating Activities	-$2.368M	-$86.33K	$4.080M
Capital Expenditures	$1.103M	$28.58K	-$14.48K
Free Cash Flow	-$3.471M	-$114.9K	$4.095M
YoY Change	-1136.28%	-102.81%	133.98%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q4	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	3990440	usd
CY2023Q1	dei	Entity File Number EntityFileNumber	001-38543
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-1265381
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	400 Water Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 200
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Rochester
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MI
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	48307
CY2023Q1	dei	City Area Code CityAreaCode	248
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	651-6568
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2023Q1	dei	Trading Symbol TradingSymbol	OPRX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17127708	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16443666	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18208685	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	57258234	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	55931821	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18164687	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22155301	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4014853	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2280828	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	95881440	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	98576635	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143924	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	137448	usd
CY2023Q1	us-gaap	Goodwill Goodwill	22673820	usd
CY2022Q4	us-gaap	Goodwill Goodwill	22673820	usd
CY2023Q1	oprx	Technology Assets Net TechnologyAssetsNet	7591461	usd
CY2022Q4	oprx	Technology Assets Net TechnologyAssetsNet	7702895	usd
CY2023Q1	us-gaap	Mineral Properties Net MineralPropertiesNet	1886008	usd
CY2022Q4	us-gaap	Mineral Properties Net MineralPropertiesNet	1940178	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	213324	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	235320	usd
CY2023Q1	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3302563	usd
CY2022Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	3384889	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	35667176	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	35937102	usd
CY2023Q1	us-gaap	Assets Assets	131692540	usd
CY2022Q4	us-gaap	Assets Assets	134651185	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1288854	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1549979	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2124777	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2601246	usd
CY2023Q1	oprx	Revenue Share Payable Current RevenueSharePayableCurrent	3367483	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	89287	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	89902	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	735140	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7605541	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8395876	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	123227	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	144532	usd
CY2023Q1	us-gaap	Liabilities Liabilities	7728768	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8540408	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	166666667	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18331511	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18331511	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18288571	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18288571	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	18332	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	18289	usd
CY2023Q1	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1214398	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	1214398	shares
CY2023Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1214	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1214	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	177036466	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	172785800	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-53089812	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-46692098	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	123963772	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	131692540	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	134651185	usd
CY2023Q1	us-gaap	Revenues Revenues	13002910	usd
CY2022Q1	us-gaap	Revenues Revenues	13731530	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	5569621	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	5629858	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	7433289	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	8101672	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	14032542	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	11391233	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	463933	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	471540	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	14496475	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	11862773	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7063186	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3761101	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	665472	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6397714	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3761098	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6397714	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3761098	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17094676	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17878068	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17094676	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17878068	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	126110777	usd
CY2023Q1	oprx	Stockbased Compensation Expense Options StockbasedCompensationExpenseOptions	1466694	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2913809	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	40606	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	-170400	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6397714	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	123963772	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	131379717	usd
CY2022Q1	oprx	Stockbased Compensation Expense Options StockbasedCompensationExpenseOptions	905744	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	2268354	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	258128	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3761098	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	131050845	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-6397714	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3761098	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	463933	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	471540	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4380503	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3174098	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	128178	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	21000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-3862436	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5643761	usd
CY2023Q1	oprx	Lease Liabilities Arising From Right Of Use Assets LeaseLiabilitiesArisingFromRightOfUseAssets	-1734024	usd
CY2022Q1	oprx	Lease Liabilities Arising From Right Of Use Assets LeaseLiabilitiesArisingFromRightOfUseAssets	1021166	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-261125	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-6079	usd
CY2023Q1	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-622956	usd
CY2022Q1	oprx	Increase Decrease In Revenue Share Payable IncreaseDecreaseInRevenueSharePayable	-1202497	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-476392	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-1184784	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	570831	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-96863	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-86330	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	4080244	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	28580	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14480	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	56926611	usd
CY2023Q1	oprx	Redemptions Of Heldtomaturity Investments RedemptionsOfHeldtomaturityInvestments	-55600198	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	51271	usd
CY2023Q1	us-gaap	Payments For Software PaymentsForSoftware	193901	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1548894	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-65751	usd
CY2023Q1	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid	170400	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	40606	usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	258128	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-129794	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	258128	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1765018	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4272621	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	18208685	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	84681770	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	16443667	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	88954391	usd
CY2023Q1	oprx	Us Healthcare Providers Percentage USHealthcareProvidersPercentage	0.60	pure
CY2023Q1	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	We also had a lease on office space in Cranbury, New Jersey, which expired in January 2022. For leases that contain renewal options, we have only assumed renewal for the headquarters lease.
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	2992909	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3582735	usd
CY2023Q1	us-gaap	Deferred Revenue DeferredRevenue	735140	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	164309	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	164309	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	-8778893	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	9349724	usd
CY2023Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	735140	usd
CY2023Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	13002910	usd
CY2022Q1	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	13731530	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	24696	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	28023	usd
CY2023Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	8063	usd
CY2022Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	8092	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	32759	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	36115	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	73860	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	80253	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	70224	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	224337	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	11823	usd
CY2023Q1	oprx	Total Lease Liability TotalLeaseLiability	212514	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045	pure
CY2023Q1	oprx	Measurement Of Lease Liabilities MeasurementOfLeaseLiabilities	22185	usd
CY2022Q1	oprx	Measurement Of Lease Liabilities MeasurementOfLeaseLiabilities	24493	usd
CY2023Q1	oprx	Repayments Of Short Term Capital Lease Obligations RepaymentsOfShortTermCapitalLeaseObligations	24620	usd
CY2022Q1	oprx	Repayments Of Short Term Capital Lease Obligations RepaymentsOfShortTermCapitalLeaseObligations	27898	usd
CY2023Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	24696	usd
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	28023	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	9668	shares
CY2023Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	170400	usd
CY2022Q4	us-gaap	Common Stock Other Value Outstanding CommonStockOtherValueOutstanding	20000000	usd
CY2022	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	1214398	shares
CY2022	us-gaap	Insurance Commissions InsuranceCommissions	20021830	usd
CY2023Q1	oprx	Remaining Expenses RemainingExpenses	11021446	usd
CY2023Q1	oprx	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm2	P1Y10M28D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	392669	usd
CY2023Q1	oprx	Restricted Stock Granted Remains Value RestrictedStockGrantedRemainsValue	14830343	usd
CY2023Q1	oprx	Remains To Be Recognized Over A Period RemainsToBeRecognizedOverAPeriod	P1Y10M24D
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2913809	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2268354	usd
CY2023Q1	oprx	Market Based Equity Grants MarketBasedEquityGrants	1503359	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-6397714	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-3761098	usd
CY2023Q1	oprx	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	17094676	shares
CY2022Q1	oprx	Weighted Average Number Of Share Outstanding Basic WeightedAverageNumberOfShareOutstandingBasic	17878068	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17094676	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17878068	shares
CY2023Q1	oprx	Basicin Per Share BasicinPerShare	-0.37
CY2022Q1	oprx	Basicin Per Share BasicinPerShare	-0.21
CY2023Q1	oprx	Dilutedin Per Share DilutedinPerShare	-0.37
CY2022Q1	oprx	Dilutedin Per Share DilutedinPerShare	-0.21
CY2023Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	93804	shares
CY2022Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	298697	shares
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21500000	usd
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	OptimizeRx Corp
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments		usd
CY2022Q1	oprx	Redemptions Of Heldtomaturity Investments RedemptionsOfHeldtomaturityInvestments		usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2022Q1	us-gaap	Payments For Software PaymentsForSoftware		usd
CY2022Q1	oprx	Reduction Of Evince Med Purchase Price For Amounts Previously Paid ReductionOfEvinceMedPurchasePriceForAmountsPreviouslyPaid		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2023Q1	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
CY2022Q1	oprx	Effect Of Dilutive Stock Options Warrants And Stock Grants EffectOfDilutiveStockOptionsWarrantsAndStockGrants		shares
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001448431

Files In Submission

Name	View Source	Status
0001213900-23-039060-index-headers.html	Edgar Link	pending
0001213900-23-039060-index.html	Edgar Link	pending
0001213900-23-039060.txt	Edgar Link	pending
0001213900-23-039060-xbrl.zip	Edgar Link	pending
f10q0323ex31-1_optimizerx.htm	Edgar Link	pending
f10q0323ex31-2_optimizerx.htm	Edgar Link	pending
f10q0323ex32-1_optimizerx.htm	Edgar Link	pending
f10q0323_optimizerx.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oprx-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
oprx-20230331_cal.xml	Edgar Link	unprocessable
oprx-20230331_def.xml	Edgar Link	unprocessable
oprx-20230331_lab.xml	Edgar Link	unprocessable
oprx-20230331_pre.xml	Edgar Link	unprocessable
f10q0323_optimizerx_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPRX
OptimizeRx Corp Stock $oprx

2023 Q2 Form 10-Q Financial Statement

#000121390023039060 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX OptimizeRx Corp Stock $oprx

2023 Q2 Form 10-Q Financial Statement

#000121390023039060 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPRX
OptimizeRx Corp Stock $oprx